Article citationsMore>>

Esposito, S., Lizioli, A., Lastrico, A., Begliatti, E., Rognoni, A., Tagliabue, C., Cesari, L., Carreri, V. and Principi, N. (2007) Impact on Respiratory Tract Infections If Heptavalent Pneumococcal Conjugate Vaccine Administred at 3, 5 and 11 Months of Age. Respiratory Research, 8, 12.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1804265/

has been cited by the following article:

• TITLE: Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children

  AUTHORS: María Hortal, Miguel Meny, Miguel Estevan, Fernando Arrieta, Hilda Laurani

  KEYWORDS: Pneumococcal Conjugate Vaccine, Pneumonia, Birth Cohort, Incidence Rate, Dose Schedule

  JOURNAL NAME: World Journal of Vaccines, Vol.5 No.1, January 20, 2015

  ABSTRACT: The 7-valent pneumococcal conjugate vaccine (PCV) was introduced in Uruguay in March 2008. In April 2010, it was replaced by PCV13. Surveillance of both vaccines was performed on hospitalized children with consolidated pneumonia. The effect of different number of vaccine doses was evaluated in 2008 and 2010 birth cohorts vaccinated with PCV7 and PCV13 respectively. The study aims to estimate the effects of PCV7 and PCV13 different number of doses on consolidated pneumonia, through the study of hospitalized children from 2008 and 2010 birth cohorts. Vaccination records of every child were available providing precise vaccination data; therefore a new approach was used to estimate PCVs effect. Incidence rate was calculated for each year of the study and for the different number of vaccine doses used each year. Exposure was calculated as person per year and rate ratio values determined the decrease of consolidated pneumonias. This decrease in percentage was estimated as the difference between the incidence with no vaccine and the incidence of every one of the doses. Incidence rate ratio revealed significant values for the three vaccine doses of PCVs for both cohorts. Upon comparing incidences, significant reduction percentages of consolidated pneumonia admissions were found. The reduction percentage of consolidated pneumonia for fully vaccinated (3 doses) patients was 69.3% and 84.6 % for PCV7 and PCV13, respectively. These results confirm that PCV7 and PCV13 are highly effective for reducing pediatric hospitalizations due to consolidated pneumonia, as reported by other national publications and demonstrated by international researchers.